Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PFE Pfizer	$25.36 +0.6%	$26.06	$24.48 ▼ $31.54	$143.80B	0.61	39.09 million shs	53.46 million shs
REGN Regeneron Pharmaceuticals	$634.23 -0.5%	$683.88	$618.57 ▼ $1,211.20	$69.34B	0.27	674,975 shs	1.07 million shs
VRTX Vertex Pharmaceuticals	$484.82 -1.6%	$476.45	$377.85 ▼ $519.88	$124.50B	0.41	1.28 million shs	2.23 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PFE Pfizer	0.00%	-3.83%	-4.65%	-4.61%	-9.19%
REGN Regeneron Pharmaceuticals	0.00%	-3.21%	-8.78%	-9.28%	-33.78%
VRTX Vertex Pharmaceuticals	0.00%	-2.09%	+2.69%	+23.37%	+17.87%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PFE Pfizer	4.9865 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
REGN Regeneron Pharmaceuticals	4.8189 of 5 stars	4.4	3.0	1.7	2.3	4.0	1.7	1.9
VRTX Vertex Pharmaceuticals	3.8304 of 5 stars	2.3	3.0	0.0	3.3	3.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PFE Pfizer	2.63	Moderate Buy	$31.92	25.90% Upside
REGN Regeneron Pharmaceuticals	2.76	Moderate Buy	$966.88	52.45% Upside
VRTX Vertex Pharmaceuticals	2.65	Moderate Buy	$508.65	4.92% Upside

Current Analyst Ratings Breakdown

Latest PFE, VRTX, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/31/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$1,100.00 ➝ $1,000.00
3/31/2025	VRTX Vertex Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$555.00 ➝ $567.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/20/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$407.00 ➝ $408.00
2/11/2025	VRTX Vertex Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Hold	$408.00 ➝ $424.00
2/11/2025	VRTX Vertex Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$460.00 ➝ $520.00
2/11/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$402.00 ➝ $407.00
2/11/2025	VRTX Vertex Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$435.00 ➝ $467.00
2/11/2025	VRTX Vertex Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$480.00 ➝ $480.00

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PFE Pfizer	$63.63B	2.26	$3.97 per share	6.38	$15.81 per share	1.60
REGN Regeneron Pharmaceuticals	$14.20B	4.88	$41.64 per share	15.23	$268.50 per share	2.36
VRTX Vertex Pharmaceuticals	$11.02B	11.30	N/A	N/A	$63.90 per share	7.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PFE Pfizer	$8.03B	$1.41	17.98	8.37	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$38.28	16.57	16.68	2.34	31.07%	16.32%	12.76%	4/29/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$2.20	N/A	27.69	2.11	-4.86%	-2.02%	-1.49%	5/5/2025 (Estimated)

Latest PFE, VRTX, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/10/2025	Q4 2024	VRTX Vertex Pharmaceuticals	$3.99	$3.54	-$0.45	$3.50	$2.78 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
2/4/2025	Q4 24	REGN Regeneron Pharmaceuticals	$11.21	$12.07	+$0.86	$8.06	$3.76 billion	$3.79 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PFE Pfizer	$1.72	6.78%	+2.50%	121.99%	16 Years
REGN Regeneron Pharmaceuticals	$0.88	0.14%	N/A	2.30%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest PFE, VRTX, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PFE Pfizer	0.63	1.00	0.73
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PFE Pfizer	68.36%
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
PFE Pfizer	0.06%
REGN Regeneron Pharmaceuticals	7.48%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.79 million	256.28 million	Optionable

PFE, VRTX, and REGN Headlines

Recent News About These Companies

Clearbridge Investments LLC Has $745.34 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 7:20 AM | marketbeat.com

Joseph Group Capital Management Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 6:31 AM | marketbeat.com

California Public Employees Retirement System Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 6:24 AM | marketbeat.com

Allstate Corp Makes New $3.07 Million Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 5:11 AM | marketbeat.com

Blair William & Co. IL Has $10.73 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 31 at 4:37 AM | marketbeat.com

Vertex Pharmaceuticals: Advancements in T1D Program and Strategic Focus on Innovative Therapies Justify Buy Rating

March 30 at 11:03 PM | tipranks.com

Allianz SE Invests $9.59 Million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 30 at 7:19 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Pictet Asset Management Holding SA

March 30 at 5:53 AM | marketbeat.com

Nomura Asset Management Co. Ltd. Sells 5,095 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 30 at 5:35 AM | marketbeat.com

New Age Alpha Advisors LLC Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 30 at 5:34 AM | marketbeat.com

Vertex Pharmaceuticals: Strategic Advancements and Promising Market Potential Drive Buy Rating

March 29 at 12:02 PM | tipranks.com

DnB Asset Management AS Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 29 at 7:19 AM | marketbeat.com

denkapparat Operations GmbH Makes New $399,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 29 at 6:57 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by UniSuper Management Pty Ltd

March 29 at 5:38 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by WINTON GROUP Ltd

March 29 at 5:22 AM | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Acquires 32,739 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 29 at 5:14 AM | marketbeat.com

Vertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should Know

March 28 at 10:02 PM | msn.com

Is Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?

March 28 at 8:28 PM | insidermonkey.com

Vertex Pharmaceuticals (VRTX) Halts VX-264 Development, Incurs $400M Impairment

March 28 at 6:43 PM | gurufocus.com

Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

March 28 at 8:58 AM | benzinga.com

Norges Bank Buys New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 28 at 7:40 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFE, VRTX, and REGN Company Descriptions

Pfizer NYSE:PFE

$25.36 +0.15 (+0.58%)

Closing price 03:59 PM Eastern

Extended Trading

$25.30 -0.06 (-0.24%)

As of 06:44 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Regeneron Pharmaceuticals NASDAQ:REGN

$634.23 -3.13 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$619.50 -14.73 (-2.32%)

As of 06:37 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$484.82 -7.87 (-1.60%)

Closing price 04:00 PM Eastern

Extended Trading

$481.73 -3.09 (-0.64%)

As of 06:01 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time